SCHEMBL4806744

SCHEMBL4806744

COc1ccc(Cn2cnc(-c3ccccc3)c2C(OC)OC)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.53
CYP11B2 P19099 2/20 0.53
HPGD P15428 1/20 0.45
PTGS2 P35354 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP19A1 P11511 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CTSL P07711 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4798966 0.78 CYP11B1 (0.53) CYP11B1CYP11B2HPGDPTGS2CYP1A2
SCHEMBL4796428 0.78 CYP11B2 (0.53) CYP11B1CYP11B2HPGDPTGS2SIGMAR1
SCHEMBL10993362 0.76 PTGS2 (0.64) CYP11B1CYP11B2HPGDPTGS2CYP1A2
SCHEMBL27915572 0.72 PTGS2 (0.55) CYP11B1CYP11B2HPGDPTGS2CYP1A2
SCHEMBL27934319 0.70 PTGS2 (0.55) CYP11B1CYP11B2HPGDPTGS2CYP1A2
SCHEMBL27915575 0.70 PTGS2 (0.52) CYP11B1CYP11B2HPGDPTGS2L3MBTL1
SCHEMBL1950743 0.69 CYP11B1 (1.00) CYP11B1CYP11B2SIGMAR1
SCHEMBL20232995 0.69 L3MBTL1 (0.60) CYP11B1CYP11B2HPGDCYP1A2CYP2C19
SCHEMBL27915593 0.69 PDE10A (0.52) CYP11B1CYP11B2HPGDPTGS2CYP1A2
SCHEMBL12771538 0.69 HTT (0.72) CYP11B1CYP11B2HPGDNPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7427616-B2 Condensed pyridines and pyrimidines with tie2 (TEK) activity ASTRAZENECA AB (SE) 2008-09-23 US disclosed
EP-1537112-B1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2006-04-19 EP disclosed
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity ASTRAZENECA AB (SE) 2005-11-17 US disclosed
CN-1688579-A Condensed pyridines and pyrimidines with TIE2 (TEK) activity ASTRAZENECA AB (SE) 2005-10-26 CN disclosed
EP-1537112-A1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY Astrazeneca AB (SE) 2005-06-08 EP disclosed
WO-2004013141-A1 CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY ASTRAZENECA AB (SE) 2004-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256140-A1 Condensed pyridines and pyrimidines with tie2 (tek) activity TIE1, TEK, KDR CYP11B1 3361/4885CYP11B2 2474/4885HPGD 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.